Bevacizumab was the first clinically available VEGF inhibitor, and the additive impact of the bevacizumab with atezolizumab in HCC was first recognised in phase 1b GO30140 study which demonstrated significant improvement in progression free survival (PFS) with A/B compared to atezolizumab monotherapy (5.6 vs 3.6 months, hazard ratio (HR) 0.55; 80% CI 0.40–0.74; p = 0.01)6. Here, VEGFA is linked to hepatocellular carcinoma.